NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

Warren Stone, President and Chief Operating Officer of NeoGenomics

“We view this strategic partnership as vital to the future of integrated oncology diagnostics”

Warren Stone, President and Chief Operating Officer of NeoGenomics

“By scaling our digital pathology infrastructure with Indica Labs, we will have the ability to provide our pathologists and clinicians with more consistent, efficient workflows, while building the foundation we need to keep pace as AI becomes a core capability in cancer diagnosis and therapy selection. Ultimately, this is about giving the patients we serve access to faster, lifesaving decisions and informed care.”

Steven Hashagen, CEO of Indica Labs

“This expanded partnership represents an important step in building the infrastructure needed for the next generation of oncology care. By combining NeoGenomics’ precision medicine expertise and scale with Indica Labs’ flexible digital pathology platform, we are creating an AI-ready foundation that can evolve alongside a rapidly advancing biomarker and companion diagnostic landscape”

Steven Hashagen, CEO of Indica Labs

“Importantly, we believe that this partnership positions us to bring emerging diagnostic innovations into clinical practice more efficiently, support future AI and clinical trial collaborations, and ultimately give providers and patients more timely access to the insights that can help guide treatment decisions.”

Beth Palla, Head of Breast Pathology, Scripps Clinic Medical Group

“Reliable image analysis is essential for accurate breast cancer diagnostics and treatment”

Beth Palla, Head of Breast Pathology, Scripps Clinic Medical Group

“NeoGenomics has been a trusted partner in our digital pathology operations for years, and we expect these expanded capabilities to mark a major step forward that will directly transform our daily practice.”